Related Experiment Video
Updated: Mar 28, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
Peter Johansson1, Lauren G Aoude1, Karin Wadt2
1QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Abstract:
Next generation sequencing of uveal melanoma (UM) samples has identified a number of recurrent oncogenic or loss-of-function mutations in key driver genes including: GNAQ, GNA11, EIF1AX, SF3B1 and BAP1. To search for additional driver mutations in this tumor type we carried out whole-genome or whole-exome sequencing of 28 tumors or primary cell lines. These samples have a low mutation burden, with a mean of 10.6 protein changing mutations per sample (range 0 to 53). As expected for these sun-shielded melanomas the mutation spectrum was not consistent with an ultraviolet radiation signature, instead, a BRCA mutation signature predominated. In addition to mutations in the known UM driver genes, we found a recurrent mutation in PLCB4 (c.G1888T, p.D630Y, NM_000933), which was validated using Sanger sequencing. The identical mutation was also found in published UM sequence data (1 of 56 tumors), supporting its role as a novel driver mutation in UM. PLCB4 p.D630Y mutations are mutually exclusive with mutations in GNA11 and GNAQ, consistent with PLCB4 being the canonical downstream target of the former gene products. Taken together these data suggest that the PLCB4 hotspot mutation is similarly a gain-of-function mutation leading to activation of the same signaling pathway, promoting UM tumorigenesis.
Insights
Researchers discovered a new driver mutation, PLCB4 p.D630Y, in uveal melanoma (UM). This gain-of-function mutation activates the same signaling pathway as known UM drivers, suggesting a key role in tumor development.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Uveal melanoma (UM) is the most common primary intraocular malignancy.
- Previous next-generation sequencing studies identified key driver mutations in GNAQ, GNA11, EIF1AX, SF3B1, and BAP1.
Purpose of the Study:
- To identify novel driver mutations in uveal melanoma.
- To investigate the role of PLCB4 mutations in UM tumorigenesis.
Main Methods:
- Whole-genome and whole-exome sequencing of 28 UM tumors and cell lines.
- Sanger sequencing for mutation validation.
- Analysis of published UM sequencing data.
Main Results:
- A recurrent PLCB4 mutation (p.D630Y) was identified and validated in UM samples.
- This mutation was mutually exclusive with GNA11 and GNAQ mutations.
- The PLCB4 mutation signature predominated over UV signatures, suggesting a BRCA-like mutational process.
Conclusions:
- PLCB4 p.D630Y represents a novel, recurrent, gain-of-function driver mutation in uveal melanoma.
- This mutation likely activates the same oncogenic signaling pathway as GNA11/GNAQ mutations.
- The findings provide new insights into UM pathogenesis and potential therapeutic targets.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene

